ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Renewed Hope For Mild Alzheimer's Patients As NICE Process On Anti-Dementia Medicines Ruled Unfair, UK
Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride)
and Pfizer Limited, its co-promotion partner, welcomed today's landmark
ruling by the Court of Appeal. The Court found that the process by which the
National Institute for Health and Clinical Excellence (NICE) decided to
restrict anti-dementia medicines for newly diagnosed patients with mild
Alzheimer's disease was procedurally unfair.
In its ruling, the Court of Appeal stated that procedural fairness
required NICE to release a fully executable version of the cost-effectiveness
model it used to produce guidance for the treatment of patients with
Alzheimer's. The Court also found that refusal by NICE to release the model
put consultees at significant disadvantage in challenging its reliability.
Commenting on today's positive ruling Nick Burgin, Managing Director of
Eisai Ltd said: "We believe that this decision represents a victory for
common sense. As soon as we have reviewed their cost-effectiveness
calculations we will submit any new findings to NICE. We hope that this
action will ultimately restore access to anti-dementia medicines for those
patients at the mild stages of Alzheimer's disease," he concluded.
John Young, Managing Director of Pfizer Limited, said: "Contrary to
NICE's position that they follow a fully fair and transparent process, the
Court of Appeal found that this is not the case. The failure of NICE to
disclose these fundamentally important calculations has impaired the ability
of stakeholders to engage fully in the appraisal process in order to provide
final guidance that truly helps budget holders and clinicians make the best
quality decision possible for individual patients."
Eisai and Pfizer are fully committed to working with NICE to ensure that
all patients in the UK with mild to moderate Alzheimer's disease will have
access to these medicines.
http://www.eisai.co.uk
View drug information on ARICEPT.
Noua speranþã pentru pacienþii cu insuficienþã hepaticã uºoarã Alzheimer's ca procesul de la Nisa demenþã medicamente anti-neloiale, a hotãrât, Marea Britanie - Renewed Hope For Mild Alzheimer's Patients As NICE Process On Anti-Dementia Medicines Ruled Unfair, UK - articole medicale engleza - startsanatate